Veteran biotech figure Robert Langer has come up with a new venture, partnering with his daughter Susan on the launch of new gene-silencing player Soufflé Therapeutics.

资深生物技术人物罗伯特·兰格（Robert Langer）参与了一项新创业项目，与他的女儿苏珊合作推出了基因沉默领域的新公司Soufflé Therapeutics。

Watertown, Massachusetts-based Soufflé has emerged onto the scene with an impressive $200 million Series A and a mission to develop small interfering RNA (siRNA) medicines, according to a LinkedIn

马萨诸塞州沃特敦的Soufflé公司已崭露头角，获得了令人印象深刻的2亿美元A轮融资，并致力于开发小干扰RNA（siRNA）药物，据LinkedIn称。

post

帖子

from the new company's official account.

来自新公司的官方账号。

Langer has joined forces with MIT scientists Daniel Anderson and Brad Pentelute and former Alnylam scientist and genetic medicine scientist Victor Kotelianski to found Soufflé, which will focus on cell-specific ligands to deliver siRNA-based medicines 'that are rationally designed and transferred across the cell membrane to their target.'.

兰格与麻省理工学院科学家丹尼尔·安德森和布拉德·彭特鲁特以及前阿尔尼拉姆科学家、基因药物科学家维克多·科特利亚斯基共同创立了舒芙蕾公司，该公司将专注于细胞特异性配体，以递送“经过理性设计并跨越细胞膜传递至目标”的基于siRNA的药物。

The post says that Soufflé has already secured more than $3.5 billion in fundraising and partnerships, with alliances already in place with several pharma groups including AbbVie, Amgen, Bayer and Novo Nordisk.

帖子称，Soufflé 已经筹集了超过 35 亿美元的资金并达成合作伙伴关系，并且已经与包括艾伯维、安进、拜耳和诺和诺德在内的多家制药集团建立了联盟。

Its initial focus will be on using the technologies to target skeletal muscle cells and cardiomyocytes, and include programmes due to start clinical testing next year for facioscapulohumeral muscular dystrophy (FSHD) and genetically-driven cardiomyopathies targeting a mutation of the phospholamban (PLN) gene.

其初始重点将是利用这些技术靶向骨骼肌细胞和心肌细胞，并包括预计将于明年开始临床试验的面肩肱型肌营养不良症（FSHD）和针对磷脂酰胆碱蛋白（PLN）基因突变的遗传性心肌病项目。

It is also working on heart failure and metabolic disorders..

它还致力于心力衰竭和代谢紊乱的研究。

Soufflé is led by Polaris Partners' Amir Nashat, with Susan Langer serving as chief business officer.

Soufflé由Polaris Partners的Amir Nashat领导，Susan Langer担任首席商务官。

'What Soufflé is doing is special,' said Robert Langer, who recently launched a biotech investment group,

“苏芙蕾正在做的事情很特别，”最近创立了一家生物技术投资集团的罗伯特·兰格说道，

T.Rx Capital

T.Rx资本

, with his son Michael. 'You don't see this kind of progress very often. How to deliver genetic medicines to cells outside the liver and ensure they are internalised has been a long-standing challenge in drug development. At Soufflé, we can now achieve this.'

，和他的儿子迈克尔。‘你很少看到这种进展。如何将基因药物递送到肝脏以外的细胞并确保它们被内化一直是药物开发中的长期挑战。在Soufflé，我们现在可以实现这一目标。’

Other financings

其他融资

The last few days have been a fertile period for private financing of biotechs, with five other deals above or around the $100 million mark.

过去几天是生物技术公司私人融资的丰收期，有五笔交易达到或接近1亿美元。

Expedition Therapeutics

治疗探险公司

of San Francisco, California, raised $165 million in its first-round financing that has been earmarked for the clinical development of EXPD-101, described as a phase 2–ready, once-daily, oral DPP1 inhibitor – licensed from China's Fosun Pharma in a $645 million deal in August – which is being developed as a potential first-in-class therapy for chronic obstructive pulmonary disease (COPD)..

加利福尼亚州旧金山的公司在其第一轮融资中筹集了1.65亿美元，这笔资金已被指定用于EXPD-101的临床开发。EXPD-101被描述为一种处于第二阶段准备阶段的、每日一次的口服DPP1抑制剂，该药物是从中国的复星医药以6.45亿美元的交易中获得许可的，目前正被开发为一种潜在的首创慢性阻塞性肺病（COPD）治疗方法。

The round was co-led by Sofinnova Investments and Novo Holdings, with participation from Forbion, KKR's Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing investors BVF Partners and Venrock Healthcare Capital Partners.

本轮融资由索菲诺瓦投资公司和诺和控股共同领投，参与者包括福布斯、KKR的黎明生物制药、阿德格、巴拉斯尼、罗格斯资本、赛诺菲风险投资，以及现有投资者BVF合伙人和Venrock医疗资本合伙人。

Another biotech developing next-generation URAT1 inhibitors for gout and related diseases, San Diego's

另一家开发下一代URAT1抑制剂用于治疗痛风及相关疾病的生物技术公司，位于圣地亚哥的

Arthrosi Therapeutics

关节炎治疗学

, has added to its coffers with a $153 million Series E that takes the total it has raised since it was founded in 2018.

，通过一笔1.53亿美元的E轮融资增加了其金库，使其自2018年成立以来的融资总额达到了新的高度。

The financing – led by Prime Eight Capital and backed up by CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech, and existing shareholders – will help to fund ongoing phase 3 trials of lead drug pozdeutinurad for the treatment of gout and tophaceous gout, a particularly severe form of the excruciatingly painful disease.

这笔融资由 Prime Eight Capital 领投，CR Biotech、HighLight Capital、HM Venture Partners、ReliantTech 以及现有股东跟投，将有助于为正在进行的针对痛风和结节性痛风（一种特别严重的极度痛苦疾病）的主要药物 pozdeutinurad 的第三阶段试验提供资金。

Results from the REDUCE 1 and REDUCE 2 trials are due in the second quarter of 2026..

REDUCE 1 和 REDUCE 2 试验的结果预计将在 2026 年第二季度公布。

New York startup

纽约初创公司

Nilo Therapeutics

尼罗治疗学

– founded by a trio of immunology experts – made its debut this week with a $101 million Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments.

本周，这家由三位免疫学专家创立的公司首次亮相，其A轮融资达1.01亿美元，由The Column Group、DCVC Bio和Lux Capital领投，盖茨基金会和Alexandria Venture Investments参投。

The company is the brainchild of Columbia University's Charles Zuker, Yale School of Medicine's Ruslan Medzhitov, and Harvard Medical School's Steve Liberles, and has been set up to develop drugs that interact with vagal neurons in order to modify immune activation and inflammation. Their work derives from a body–brain circuit that regulates the immune system and was described in a .

该公司由哥伦比亚大学的查尔斯·祖克尔、耶鲁医学院的鲁斯兰·梅德日托夫和哈佛医学院的史蒂夫·利伯莱斯共同创立，旨在开发与迷走神经元相互作用以调节免疫激活和炎症的药物。他们的研究源于一条调节免疫系统的身体-大脑回路，该回路曾在一篇论文中被描述。

Nature

自然

paper published last year.

去年发表的论文。

Turning to Europe for a moment, Milan, Italy-based startup

转向欧洲，意大利米兰的初创公司

NanoPhoria Bioscience

纳米福利亚生物科学

made its debut with a €83.5 million ($97 million) Series A, which is reported to be the largest ever first-round investment for an Italian biotech. It was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with Panakès Partners also investing, and another undisclosed backer joining the round..

这家初创公司首次亮相便获得了8350万欧元（9700万美元）的A轮融资，据报道称这是意大利生物技术公司有史以来最大的首轮融资。此轮融资由XGEN Venture、Sofinnova Partners和CDP Venture Capital领投，Panakès Partners也参与了投资，另外还有一位未披露身份的支持者加入了此轮投资。

The cash injection will finance NanoPhoria's peptide-based NP-MP1 for heart failure with reduced ejection fraction (HFrEF) through completion of early clinical development, the setup of initial manufacturing, and regulatory activities. NP-MP1 targets cardiac L-type calcium channels and is designed to improve ejection fraction and heart muscle contractility in HFrEF patients.

现金注入将为NanoPhoria的基于肽的NP-MP1提供资金，用于射血分数降低的心力衰竭（HFrEF）的早期临床开发、初始制造的建立以及监管活动。NP-MP1靶向心脏L型钙通道，旨在改善HFrEF患者的射血分数和心肌收缩力。

It is still being prepared for human testing..

它仍在为人体试验做准备。

Finally this week,

本周终于，

TORL BioTherapeutics

TORL生物治疗公司

completed a $96 million Series C that will be deployed in the development of its lead candidate TORL-1-23, a claudin 6-targeted antibody-drug conjugate (ADC) that is currently in a phase 2 trial in platinum-resistant ovarian cancer, with a phase 3 programme scheduled to start in 2026.

完成了9600万美元的C轮融资，这笔资金将用于其主要候选药物TORL-1-23的开发，这是一种靶向claudin 6的抗体药物偶联物（ADC），目前正在铂耐药卵巢癌的二期试验中，计划于2026年开始三期试验。

The Los Angeles biotech, which did not disclose the investors behind the round, said it has taken the total raised to date above $450 million.

这家洛杉矶的生物技术公司没有透露这一轮融资背后的投资人，但表示截至目前融资总额已超过 4.5 亿美元。

Photo by

照片由

Adam Nir

亚当·尼尔

on

打开

Unsplash

Unsplash